---
title: "EGFR Mt"
slug: "egfr-mt"
date: "2023-11-19"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Molecular biology-of-NSCLC]]

# EGFR Mt

- 15% of ADCL,
- [[exon 19 deletions]](LREA) (45%),
- exon 21 L858R (40%),
- exon 18 (G719X),
- exon 20 (S768I),
- exon 21 (L861Q),
- confer EGFR TKI Sn,
- initially described in never-smokers,
- but also present in pts w/ smoking histories (JCO 2011;29:2066).
- [[Exon 20 insertions]] now targetable driver.
- Acquired [[T790M]] Mt confers resistance to earlier generation EGFR TKIs (NEJM 2005;352:786)

### Backlink

- [[management of Stage IV metastatic disease of NSCLC]]
- [[management of Pathologic stage I to IIIA NSCLC]]
- [[Pathologic stage I to IIIA (N1) of NSCLC Treatment]]
- [[Molecular biology-of-NSCLC]]
- [[Targeted therapy-of-NSCLC]]
